Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 68 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2014', provides an overview of the Chagas Disease (American Trypanosomiasis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chagas Disease (American Trypanosomiasis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chagas Disease (American Trypanosomiasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chagas Disease (American Trypanosomiasis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chagas Disease (American Trypanosomiasis) Overview 8
Therapeutics Development 9
Pipeline Products for Chagas Disease (American Trypanosomiasis) - Overview 9
Pipeline Products for Chagas Disease (American Trypanosomiasis) - Comparative Analysis 10
Chagas Disease (American Trypanosomiasis) - Therapeutics under Development by Companies 11
Chagas Disease (American Trypanosomiasis) - Therapeutics under Investigation by Universities/Institutes 12
Chagas Disease (American Trypanosomiasis) - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Chagas Disease (American Trypanosomiasis) - Products under Development by Companies 16
Chagas Disease (American Trypanosomiasis) - Products under Investigation by Universities/Institutes 17
Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development 18
Eisai Co., Ltd. 18
Merck & Co., Inc. 19
Panacela Labs, Inc. 20
Sanofi 21
Seek 22
Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
chagas disease vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
chagas disease vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cz-007 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cz-008 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drugs for Chagas Disease - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
E-1224 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
EPLBS-1246 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EPLBS-967 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
fexinidazole - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
K-777 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Monoclonal Antibody for Chagas - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NEU-321 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
posaconazole - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule for Chagas Disease - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules for Chagas Disease - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Chagas Disease - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules for Infectious Diseases - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecules for Protozoal Infections - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Inhibit Nitroreductase for Chagas Disease and African Trypanosomiasis - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VNI - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
XELRYX-3 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Chagas Disease (American Trypanosomiasis) - Recent Pipeline Updates 60
Chagas Disease (American Trypanosomiasis) - Dormant Projects 62
Chagas Disease (American Trypanosomiasis) - Discontinued Products 63
Chagas Disease (American Trypanosomiasis) - Product Development Milestones 64
Featured News & Press Releases 64
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 64
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 64
Mar 12, 2012: DNDi Receives �2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2014 9
Number of Products under Development for Chagas Disease (American Trypanosomiasis) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co., Ltd., H2 2014 18
Chagas Disease (American Trypanosomiasis) - Pipeline by Merck & Co., Inc., H2 2014 19
Chagas Disease (American Trypanosomiasis) - Pipeline by Panacela Labs, Inc., H2 2014 20
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H2 2014 21
Chagas Disease (American Trypanosomiasis) - Pipeline by Seek, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Chagas Disease (American Trypanosomiasis) Therapeutics - Recent Pipeline Updates, H2 2014 60
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H2 2014 62
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H2 2014 63